SCHEMBL4032832

SCHEMBL4032832

O=C(Nc1ccc(CO)cc1)C1CN(C(=O)C(c2ccccc2)c2ccccc2)CCN1S(=O)(=O)c1cccs1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
RAB9A P51151 2/20 0.42
ALDH1A1 P00352 3/20 0.42
GAA P10253 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
POLB P06746 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
UBE2N P61088 1/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
RECQL P46063 1/20 0.40
ELOVL6 Q9H5J4 1/20 0.40
HCRTR1 O43613 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4032756 0.84 ALDH1A1 (0.51) MEN1KMT2ARAB9AALDH1A1GAA
SCHEMBL4038593 0.82 ALDH1A1 (0.51) RAB9AALDH1A1HTTSMN1; SMN2L3MBTL1
SCHEMBL4035013 0.82 MEN1 (0.46) MEN1KMT2ARAB9AALDH1A1SMN1; SMN2
SCHEMBL4036042 0.81 PKM (0.53) RAB9AALDH1A1GAAHTTSMN1; SMN2
SCHEMBL1382447 0.81 ALDH1A1 (0.46) MEN1KMT2AALDH1A1GAASMN1; SMN2
SCHEMBL4038120 0.80 GAA (0.49) MEN1KMT2AALDH1A1GAAL3MBTL1
SCHEMBL4032732 0.79 GAA (0.54) KMT2AALDH1A1GAAHTTSMN1; SMN2
SCHEMBL4035588 0.78 ALDH1A1 (0.59) MEN1KMT2AALDH1A1GAAHTT
SCHEMBL4035457 0.78 CHRM5 (0.45) GAAPOLBMAPTHCRTR1HCRTR2
SCHEMBL4033382 0.76 POLB (0.43) MEN1KMT2AALDH1A1GAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1592389-B1 PIPERAZINE-2-CARBOXAMIDE DERIVATIVES SERONO LAB (CH) 2009-04-22 EP claimed
US-20070142391-A1 Piperazine-2-carboxamide derivatives MERCK SERONO SA (CH) 2007-06-21 US claimed
US-8404690-B2 Piperazine-2-carboxamide derivatives MERCK SERONO SA (CH) 2013-03-26 US disclosed
EP-1592389-B1 PIPERAZINE-2-CARBOXAMIDE DERIVATIVES SERONO LAB (CH) 2009-04-22 EP disclosed
US-20070142391-A1 Piperazine-2-carboxamide derivatives MERCK SERONO SA (CH) 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142391-A1 Piperazine-2-carboxamide derivatives P2RX5, P2RX2, NPY5R MEN1 4821/4885KMT2A 396/4885RAB9A 4023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.